2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Outstanding mix of clinical abstracts, including clinical trials, retrospective analysis, and molecular observations in myelofibrosis, polycythemia vera, essential thrombocythemia and other myeloid neoplasms
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2050 Efficacy and safety of the RD regimen (Lenalidomide, Dexamethasone) in the treatment of rosai-dorfman disease: A prospective, multicenter, single-arm study.

Long Chang, MD, Yajing Lu2, Wei-tong Liu3, Yaguan Fan4, Fengjuan Li5, Dao-Bin Zhou6, Jiayi Liu7, Xinxin Cao, MD8
1 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
2 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
3 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
4 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
5 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
6 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
7 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
8 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

 Background

Rosai-Dorfman disease (RDD) is a rare heterogeneous histiocytic disorder lacking standardized first-line treatment. Our prior single-center, prospective investigation (NCT 04924647) demonstrated the remarkable efficacy of combined lenalidomide and dexamethasone (RD) therapy in patients with RDD. The present study reports a multicenter prospective phase 2 clinical trial (NCT 07187167) together with an extended follow-up of earlier data conducted between June 2021 and December 2025.

Method

Sixty newly diagnosed and thirty-six recurrent RDD patients were enrolled. Lenalidomide 25mg days 1-21 plus dexamethasone 40mg days 1,8,15,22 was administered in 28-day cycles, totaling 12 cycles. Every patient received aspirin thromboprophylaxis during the RD treatment. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall response rate (ORR) to RD regimen, toxicity, and overall survival (OS) measured from RD start to death or last follow-up. The ?nal follow-up was June 1, 2026.

Result

The median age was 45 years (IQR 35-55), with 44.8% (n = 43) being male. Ninety-four patients (97.9%) exhibited extranodal RDD (10 unifocal, 21 single-system multifocal, 63 multi-system). A history of connective tissue disease was documented in 4 patients (4.2%). Median number of involved organs was 2 (range 1–7, IQR 1–3). The most frequently involved sites included lymph nodes (n = 39, 40.6%), subcutaneous tissue (n = 32, 33.3%), bone (n = 32, 33.3%), laryngopharynx (n = 25, 26.0%), sinus (n = 19, 19.8%) and central nervous system (CNS, n = 19, 19.8%). Among 84 patients undergoing next generation sequencing, MAP2K1, KRAS and BRAF non-V600E alterations were identified in 18 (21.4%) ,15 (14.3%) and 4 (4.8%) patients, respectively. Elevated C-reactive protein, IL-6, IL-10, TNF-α and IgG-4 were observed in 21.8% (19/87), 43.9% (36/82), 43.9% (36/82), 57.7% (45/78) and 12.7% (7/55) patients, respectively.

Patients received a median of 12 cycles therapy (IQR 6-12), while 12 (12.5%) went off protocol due to patient decision (n=6), disease progression (n=3) and adverse effect (n=3) before the last follow up. Among 85 evaluable patients, the ORR was 92.9%, comprising 43.5% complete remission and 49.4% partial remission as the best response. Five patients (5.2%) had stable disease (SD) and one (1.1%) had progressive disease (PD).

With a median follow up of 24 months (IQR 11-36), three patients in this cohort died (1 due to myocardial infarction, 1 due to COVID-19 and 1 due to CNS progression) and 12 experienced disease progression. The estimated 3- year OS and PFS rates were 96.1% and 76.8%, respectively. Univariate prognostic for PFS showed patients with 1-3 involved organs (3y PFS 81.8% vs 52.4%, HR 0.22, 95% CI 0.05–0.93, P=0.039) and those achieving CR (3y PFS 87.1% vs 58.7%, HR 0.12, 95% CI 0.03–0.33, P<0.001) exhibited better outcomes. Newly diagnosed patients tend to have better PFS than recurrent (3y PFS 84.4% vs 60.6%, HR 0.40, 95% CI 0.13–1.17, P<0.094).

Regarding adverse events, three patients discontinued RD therapy due to grade 3 adverse events (1 pulmonary embolism and 2 fatigue). Two patients experienced dose adjusted due to grade 3 myelosuppression. Twenty-six patients (27.0%) had grade 1-2 hematological toxicity. Other toxicities included rash (n=14, 14.5%), constipation (n=14, 14.5%), fatigue (n=12,12.5%), diarrhea (n=8,8.3%), glucose intolerance (n=8,8.3%) and edema (n=7, 7.3%).

Conclusion

Lenalidomide and dexamethasone combination regimen is a valid and safe regimen for RDD. Patients with 1-3 involved organs and achieving CR predict better outcomes.

Long Chang, MD: No relevant conflicts of interest to declare.